Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$967.98 USD
-10.23 (-1.05%)
Updated May 16, 2024 04:00 PM ET
After-Market: $967.74 -0.24 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
REGN 967.98 -10.23(-1.05%)
Will REGN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Other News for REGN
Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Biogen (BIIB)
Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
Evercore says biotech ‘winter is finally thawing’
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
Roblox downgraded, Western Digital initiated: Wall Street's top analyst calls